



Ulrich Borchers (Autor)

Mechanism of tumor progression: Valuation of selective targets for the development of novel strategies in the therapy of solid tumors

Ulrich Borchers

Mechanism of tumor progression:
Valuation of selective targets for the development
of novel strategies in the therapy of solid tumors



Cuvillier Verlag Göttingen

<https://cuvillier.de/de/shop/publications/3499>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany

Telefon: +49 (0)551 54724-0, E-Mail: info@cuvillier.de, Website: <https://cuvillier.de>

Contents

1. Introduction **6**

- 1.1. Regulation of EGF receptor activity by HK1-ceramide, a stable synthesized analogue of the ganglioside GM3-lactone. 7
- 1.2. A novel polyclonal antibody directed against the lactone form of ganglioside GM3: Analyses of its potential as tumor marker for melanomas. 9
- 1.3. Evaluation of the efficacy of novel synthetic drugs to inhibit tumor growth and progression of human pancreatic ductal adenocarcinoma. 11
- 1.3.1. Evaluation of the seco-CBI-derivative AF86.1 for its potential use in antibody directed enzyme prodrug therapy. 11
- 1.3.2. Evaluation of the antitumor and antimetastatic effect of different matrix metalloproteinase inhibitors on human pancreatic ductal adenocarcinoma in the orthotopic SCID-mouse model. 17
- 1.3.2.1. Human pancreatic ductal adenocarcinoma. 17
- 1.3.2.2. Matrix metalloproteinases. 17
- 1.3.2.3. Matrix metalloproteinase-inhibitors. 18
- 1.3.2.4. The orthotopic SCID-mouse model. 20

2. Materials and Methods **22**

- 2.1. Glycolipids. 22
- 2.2. Cell culture. 22
- 2.3. Analyses of EGF mediated tyrosine phosphorylation of EGF receptor in A431 cells. 23
- 2.4.. Determination of EGF-dependent mitogenesis. 25
- 2.5. Analyses of binding of the ¹²⁵I-EGF to cell surface receptor. 25

2.6. Animals.	26
2.7. Compounds.	27
2.8. Formulations and treatments.	27
2.9. Subcutaneous tumor implantation.	30
2.10. Orthotopic tumor implantation and tumor growth.	30
2.11. Immunohistochemistry.	31
2.12. Data analyses.	32

3. Results

3.1. Regulation of EGF receptor activity by HK1-ceramide, a stable synthesized analogue of the ganglioside GM3-lactone.	34
3.1.1. In situ effect of HK1-ceramide and HK2-ceramide on EGF-mediated tyrosine phosphorylation of EGF receptor in cultured intact A431 cells.	34
3.1.2. In situ effect of GM3 on EGF-mediated tyrosine phosphorylation of EGF receptor in cultured intact A431 cells in dependence of the pH.	38
3.1.3. Effect of HK1-ceramide on MAP kinase activity.	39
3.1.4. Effect of HK1-ceramide on specific binding activity of ¹²⁵ I-EGF to cell surface receptor.	40
3.1.5. Effect of HK1-ceramide on EGF-dependent mitogenesis in KB cells.	41
3.2. A novel polyclonal antibody directed against the lactone form of ganglioside GM3: Analyses of its potential as tumor marker for melanomas.	42
3.3. Evaluation of the efficacy of novel synthetic drugs to inhibit tumor growth and progression of human pancreatic ductal adenocarcinoma.	47
3.3.1. The orthotopic SCID-mouse model	47
3.3.1.1. Growth characteristics of PancTu 1 cells after orthotopic implantation in SCID mice.	47

3.3.2. Evaluation of the seco-CBI-derivative AF86 for its potential use in antibody directed enzyme prodrug therapy. Preliminary results <i>in vivo</i> in SCID mice.	49
3.3.2.1. Acute Toxicity	49
3.3.2.1.1. Experimental Design	50
3.3.2.1.2. Tolerance to AF86.1	51
3.3.2.2.. First investigations of AF86.1 for its potential use in antibody-directed enzyme prodrug therapy.	52
3.3.2.2.1. Experimental Design	52
3.3.3. Evaluation of the antitumor and antimetastatic effect of the MMP inhibitor AG3340 on human pancreatic adenocarcinoma in the orthotopic SCID-mouse model.	55
3.3.3.1. Study design	55
3.3.3.2. Tolerance to AG3340	55
3.3.3.3. Effects of AG3340 on tumor growth and morphological properties	56
3.3.3.4. Effects of AG3340 on tumor invasion, disseminated tumor growth and metastasis	57
3.3.4. Evaluation of the antitumor and antimetastatic effect of the chemotherapeutic agent gemcitabine on human pancreatic adenocarcinoma in the orthotopic SCID-mouse model.	60
3.3.4.1. Study design.	60